Skip to content

PDS Biotechnology Corp: 10-K filed 2018-03-01

What PDS Biotechnology Corp reported in its annual report filed 2018-03-01 (fiscal FY 2017): 33 published measures, 127 facts as tagged in accession 0001140361-18-011218.

This filing

Form
10-K (annual report)
Filed
2018-03-01
Fiscal period
fiscal FY 2017
Accession
0001140361-18-011218 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PDS Biotechnology Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2017-12-3192,621,077USD
At 2016-12-31110,914,447USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2017-12-3162,371,411USD
At 2016-12-3189,276,557USD
At 2015-12-31122,477,527USD
At 2014-12-31-27,833,747USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2017-12-3188,067,647USD
At 2016-12-31106,398,919USD
At 2015-12-31130,189,421USD
At 2014-12-3113,728,972USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-13,905,000USD92
2017-01-01 to 2017-12-31-50,859,803USD365
2017-07-01 to 2017-09-30-11,281,000USD92
2017-04-01 to 2017-06-30-13,504,000USD91
2017-01-01 to 2017-03-31-12,170,000USD90
2016-10-01 to 2016-12-31-9,516,000USD92
2016-01-01 to 2016-12-31-38,820,998USD366
2016-07-01 to 2016-09-30-10,759,000USD92
2016-04-01 to 2016-06-30-9,376,000USD91
2016-01-01 to 2016-03-31-9,170,000USD91
2015-01-01 to 2015-12-31-28,078,646USD365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-40,696,831USD365
2016-01-01 to 2016-12-31-32,188,668USD366
2015-01-01 to 2015-12-31-21,752,643USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-01-01 to 2017-12-31188,721USD365
2016-01-01 to 2016-12-31686,705USD366
2015-01-01 to 2015-12-311,305,086USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2017-01-01 to 2017-12-3122,554,280USD365
2016-01-01 to 2016-12-319,084,871USD366
2015-01-01 to 2015-12-31139,518,178USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-188,721USD365
2016-01-01 to 2016-12-31-686,705USD366
2015-01-01 to 2015-12-31-1,305,086USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2017-12-31-151,948,359USD
At 2016-12-31-101,074,968USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-01-01 to 2017-12-31-2,586,057USD365
2016-01-01 to 2016-12-31-1,845,986USD366
2015-01-01 to 2015-12-31-1,107,405USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2017-12-313,423,880USD
At 2016-12-313,418,077USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-12-316,182,841USD365
2016-01-01 to 2016-12-315,305,070USD366
2015-01-01 to 2015-12-312,899,304USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-16,124,000USD92
2017-01-01 to 2017-12-31-51,966,620USD365
2017-07-01 to 2017-09-30-10,903,000USD92
2017-04-01 to 2017-06-30-13,149,000USD91
2017-01-01 to 2017-03-31-11,791,000USD90
2016-10-01 to 2016-12-31-10,939,000USD92
2016-01-01 to 2016-12-31-39,512,146USD366
2016-07-01 to 2016-09-30-10,277,000USD92
2016-04-01 to 2016-06-30-9,264,000USD91
2016-01-01 to 2016-03-31-9,032,000USD91
2015-01-01 to 2015-12-31-26,498,818USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2017-12-3189,054,327USD
At 2016-12-31107,353,500USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-01-01 to 2017-12-312,180,143USD365
2016-01-01 to 2016-12-311,203,674USD366
2015-01-01 to 2015-12-31816,494USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2017-12-3112,866,759USD
At 2016-12-316,684,747USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2017-12-314,369,133USD
At 2016-12-313,471,032USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2017-10-01 to 2017-12-3116,124,000USD92
2017-01-01 to 2017-12-3151,966,620USD365
2017-07-01 to 2017-09-3010,903,000USD92
2017-04-01 to 2017-06-3013,149,000USD91
2017-01-01 to 2017-03-3111,791,000USD90
2016-10-01 to 2016-12-3110,939,000USD92
2016-01-01 to 2016-12-3139,512,146USD366
2016-07-01 to 2016-09-3010,277,000USD92
2016-04-01 to 2016-06-309,264,000USD91
2016-01-01 to 2016-03-319,032,000USD91
2015-01-01 to 2015-12-3126,498,818USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-01-01 to 2017-12-3134,311,650USD365
2016-01-01 to 2016-12-3124,825,379USD366
2015-01-01 to 2015-12-3117,839,951USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2017-12-3130,869,205shares
At 2016-12-3128,918,516shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2017-12-31214,309,370USD
At 2016-12-31190,341,769USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2017-12-313,729,161USD
At 2016-12-313,540,440USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2017-12-31305,281USD
At 2016-12-31122,363USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-31142,870USD
At 2016-12-31142,870USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2017-12-315,422,205USD
At 2016-12-313,213,715USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2017-12-31986,680USD
At 2016-12-31954,581USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2017-12-310USD
At 2016-12-310USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-13,905,000USD92
2017-01-01 to 2017-12-31-50,859,803USD365
2017-07-01 to 2017-09-30-11,281,000USD92
2017-04-01 to 2017-06-30-13,504,000USD91
2017-01-01 to 2017-03-31-12,170,000USD90
2016-10-01 to 2016-12-31-9,516,000USD92
2016-01-01 to 2016-12-31-38,820,998USD366
2016-07-01 to 2016-09-30-10,759,000USD92
2016-04-01 to 2016-06-30-9,376,000USD91
2016-01-01 to 2016-03-31-9,170,000USD91
2015-01-01 to 2015-12-31-28,078,646USD365

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2017-10-01 to 2017-12-31-13,905,000USD92
2017-01-01 to 2017-12-31-50,859,803USD365
2017-07-01 to 2017-09-30-11,281,000USD92
2017-04-01 to 2017-06-30-13,504,000USD91
2017-01-01 to 2017-03-31-12,170,000USD90
2016-10-01 to 2016-12-31-9,516,000USD92
2016-01-01 to 2016-12-31-38,820,998USD366
2016-07-01 to 2016-09-30-10,759,000USD92
2016-04-01 to 2016-06-30-9,376,000USD91
2016-01-01 to 2016-03-31-9,170,000USD91
2015-01-01 to 2015-12-31-32,435,054USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2017-01-01 to 2017-12-3117,654,970USD365
2016-01-01 to 2016-12-3114,686,767USD366
2015-01-01 to 2015-12-318,658,867USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-01-01 to 2017-12-31182,918USD365
2016-01-01 to 2016-12-31100,117USD366
2015-01-01 to 2015-12-3153,116USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2017-01-01 to 2017-12-311,635,562USD365
2016-01-01 to 2016-12-31790,402USD366
2015-01-01 to 2015-12-31559,175USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2017-01-01 to 2017-12-31898,101USD365
2016-01-01 to 2016-12-311,420,556USD366
2015-01-01 to 2015-12-31-71,751USD365

Inspect the source

Entity
PDS Biotechnology Corp / CIK 0001472091
Captured
2026-09-20T09:07:40.584Z
SEC response SHA-256
69e1cee7a201b49964a3008a5c2ec76eaaf5723c75824c2caf8a2c52d86edef2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001472091.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))